Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Institutions: Novo Nordisk (Denmark), Novo Nordisk (India), Yale University
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: GLP-1 receptor agonists, amylin receptor agonist, obesity, overweight, weight loss, subcutaneous administration, pharmacokinetics, safety and tolerability, treatment-emergent adverse events, gastrointestinal adverse effects, dose escalation, weight change, single ascending dose, multiple ascending dose, GLP-1 receptor, amylin
Open Access status: closed
Funders: Novo Nordisk, Apollo
OpenAlex ID: W4411475014
